CytoSorbents regains Nasdaq $1 minimum bid price compliance

• CytoSorbents regained Nasdaq compliance with the $1 minimum bid price rule, based on 10 consecutive sessions ending Sept. 21, 2026.
• Nasdaq closed the bid-price deficiency matter following notification received Sept. 22, 2026.
• Company still faces a separate Nasdaq Capital Market listing requirement tied to minimum market value of listed securities, with a Dec. 28, 2026 deadline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230700PR_NEWS_USPR_____NY54823) on September 23, 2026, and is solely responsible for the information contained therein.